stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) EBITDA
Ligand Pharmaceuticals Incorporated's EBITDA for fiscal 2025 was $71.1M, up 503.1% from $11.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $57.3M. Over the past ten years it has ranged from $11.8M (fiscal 2024) to $870.5M (fiscal 2019); the current reading is higher than 55% of that period. Ligand Pharmaceuticals Incorporated ranks 30th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $71.1M | 503.09% |
| FY2024 | $11.8M | (75.12%) |
| FY2023 | $47.4M | (14.35%) |
| FY2022 | $55.3M | (67.76%) |
| FY2021 | $171.6M | 90.62% |
| FY2020 | $90.0M | (89.66%) |
| FY2019 | $870.5M | 301.26% |
| FY2018 | $216.9M | 137.55% |
| FY2017 | $91.3M | 37.44% |
| FY2016 | $66.4M | 65.17% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$4.1M | — |
| Jun 2026 | $16.4M | (33.98%) |
| Mar 2026 | $24.9M | 23.49% |
| Dec 2025 | $20.2M | (67.89%) |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $191.8M |
| LGND Ligand Pharmaceuticals Incorporated | $57.3M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| ORKA Oruka Therapeutics, Inc. compare | −$158.0M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| IMVT Immunovant, Inc. compare | −$565.6M |
| IONS Ionis Pharmaceuticals, Inc. compare | −$579.9M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on LGND
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement